NiKang Therapeutics is an early stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs.
Location: United States, Delaware, Wilmington
Employees: 11-50
Total raised: $200M
Founded date: 2017
Investors 10
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.05.2021 | Series C | $200M | - |
Mentions in press and media 4
| Date | Title | Description |
| 10.06.2021 | Wilmington’s NiKang Therapeutics closed a $200M Series C | Biotech is to Delaware’s future as chemical engineering was to its past. When we talk about tech startups in the First State, we’re likely talking about a medical device or therapeutic rather than a web application. The latest local biotech... |
| 31.05.2021 | NiKang Therapeutics Raises $200M in Series C Financing | NiKang Therapeutics Inc., a Wilmington, Del.-based clinical stage biotech company focused on developing innovative small molecule oncology medicines, closed a $200m series C financing. The round was led by Cormorant Asset Management, HBM He... |
| 26.05.2021 | NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets | NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs, today announced the completion of an oversubscribed $200 mil... |
| - | NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets | May 26, 2021 08:00 AM Eastern Daylight Time WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with u... |